Abstract AB0572 – Figure 1

Conclusions: PCR in spot urine specimens is an accurate and convenient method to estimate the protein excretion in urine only when proteinuria is at sub nephrotic range. Prospective study is required to explore the effect of disease activity, disease duration and co-morbidities on the correlation and predictive power of the model.

REFERENCES:

Disclosure of Interest: None declared


AB0574

RENAL ACTIVITY PATTERNS AND THERAPEUTICS IN LUPUS NEPHRITIS OBSERVATIONS IN 5 MEXICAN RHEUMATOLOGY CENTRES

G. Pickens1, D.A. Herrera-van Oostdam1, F. Izarzque-Palazuelos2, S. Cerpa-Cruz3, M.A. Saavedra-Salinas4, C. Mendoza-Pinto5, C. Abd-Mendoza1.
1Rheumatology, Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi; 2Rheumatology, Centro Médico Nacional ‘20 de Noviembre’, Ciudad de México; 3Rheumatology, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara; 4Rheumatology, Hospital de Especialidades Centro Médico Nacional “La Raza”, Ciudad de México; 5Rheumatology, Hospital General Regional Numero 36 “San Alejandro”, Puebla, Mexico

Background: Lupus nephritis (LN) develops in 40%–60% of Systemic Erythematosus Lupus (SLE) patients; 45% don’t achieve complete response or eventually relapse and 10%–20% progress to end stage renal disease.

Objectives: Describe renal activity patterns and therapeutic schemes employed in 5 Mexican Rheumatology Centres.

Methods: Retrospective analysis of renal activity in 193 patients with LN with ≥6 months follow-up. If follow-up was ≤1 year, response was classified as complete (CR), partial (PR) or no response (NR). If follow up was >1 year, response was classified as one of the following patterns: persistent inactive (PI), relapsing-remitting (RR), chronic active (CA) and mixed.

Results: Biopsy was available in 166 subjects (86.01%): class IV (42.77%), III (23.49%), II (10.24%), I (9.03%). The most prevalent schemes were CYC+MMF 46.6%, only CYC 19.13%, only MMF 12.4%, CYC+MMF+ TAC 9.84%. Thirty eight patients had follow-up ≤1 year with the following response: CR 16 (42.1%), NR 13 (34.21%) y PR 9 (25.7%). One hundred and fifty five patients had >1 year follow-up with the following activity patterns: PI 55 (35.48%), RR 38 (24.51%), CA 31 (20%), mixed 31 (20%).

We then compared patients whose therapeutic schemes were classified as the National Institutes of Health regime (n=109) (as considered by the treating physician) to those with different therapeutic schemes. We observed a higher final GFR in the NIH group (79.3±10.06 ml/min/1.73 m2) compared to never smokers was 1.27 (95% CI, 0.80, 2.03). Smoking status was not associated with an antinuclear antibody, anti-SSA, anti-SSB or rheumatoid factor positivity (p=0.05). The OR of pSS comparing obese subjects with non-obese subjects was 0.79 (95% CI, 0.48, 1.30), while the OR of pSS for BMI analysed as a continuous variable was 0.97 (95% CI, 0.94, 1.01).

Conclusions: In this population-based study, current smokers have a lower risk of developing pSS while BMI does not affect this risk.

Disclosure of Interest: None declared


AB0575

CLINICAL ANALYSIS OF 22 CASES OF SYSTEMIC LUPUS ERYTHEMATOSUS COMPLICATED WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

D. xu, L. zhang, Y. Li, D. Jiang, Y. Guo, J. Tang, X. Zheng, L. Lu, Z. I. Li, G. qiao, the First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China

Objectives: To investigate the clinical features of hemophagocytic lymphohistiocytosis (HLH) in systemic lupus erythematosus (SLE).

REFERENCES:

Disclosure of Interest: None declared


AB0573

INFLUENCE OF SMOKING AND OBESITY ON THE RISK OF DEVELOPING PRIMARY SJÖGREN’S SYNDROME: A POPULATION-BASED COHORT STUDY

G. Maciel1, L. Serviol1, C. Nanni3, C. Crowson4, E. Matteson5, D. Connec6, A. Berti7, 1Maciel Hospital, Montevideo, Uruguay; 2Department of Rheumatology, Hospital of Prato, Prato, Italy; 3Mayo Clinic, Rochester MN, USA; 4Rheumatology Department, Brest Teaching Hospital, Brest, France; 5Immunology, Rheumatology, Allergy and Rare Diseases Department, San Raffaele Scientific Institute, Milan; and Rheumatology Department, Santa Chiara Hospital, Trento, Italy

Objectives: Cigarette smoking and obesity have been identified as risk factors for developing several autoimmune diseases, and may be protective for others. This study explored the role of these risk factors in primary Sjögren’s syndrome (pSS).

Methods: A cohort of Olmsted County, Minnesota residents diagnosed with pSS between January 1, 2000 and December 31, 2015 was identified based on individual medical record review. Each of the cases was matched to 3 age- and sex-matched comparators without pSS randomly selected from Olmsted County residents, indexed to the date of pSS diagnosis. Smoking status was divided into three categories of current smoker, ex-smoker and never smoker. The body weight and height closest to date of diagnosis/index date (±1 year) were used. Obesity was defined as a body mass index (BMI) >30 kg/m².

Results: 106 incident cases of pSS and 318 controls were identified. The odds ratio (OR) of pSS comparing current smokers with never smokers was 0.34 (95% confidence interval (CI): 0.14, 0.85; p<0.05), while the OR for former smokers compared to never smokers was 1.27 (95% CI, 0.80, 2.03). Smoking status was